Aiforia’s AI solutions for breast cancer diagnostics implemented at Fimlab Laboratories
Aiforia’s AI solutions for breast cancer diagnostics implemented at Fimlab Laboratories
Aiforia Technologies Plc, Press Release, October 13, 2025 at 10:00a.m. EEST
Aiforia Technologies’ AI-driven solutions for breast cancer diagnostics have been implemented at Fimlab Laboratories, marking a significant milestone in enhancing workflows and improving diagnostic quality and consistency in their pathology laboratory. Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme.
Aiforia has previously announced a multi-year framework agreement with Fimlab, under which it has been selected as one of the suppliers to support pathology diagnostics with AI. Aiforia was qualified for eight diagnostic applications, as well as for the AI model development platform.
Aiforia’s breast cancer diagnostics solutions, representing a complete suite for both breast cancer grading and biomarker panel, and featuring multiple AI models, mark the first deployment batch under the framework agreement. These solutions are now supporting routine diagnostic workflows at Fimlab. In addition, the AI model development platform has been deployed, and the collaboration has expanded to tailoring multiple AI applications for Fimlab.
“The adoption of AI is part of Fimlab’s broader development path to address the growing number of samples and the shortage of specialists in pathology. The digitalization of all tissue samples at Fimlab began as early as 2021, and now AI is taking the development to a new level. AI does not replace specialist physicians, but it supports their work and enables faster and more accurate diagnostics”, says Teemu Tolonen, Head of department at Fimlab.
“We are extremely excited to see this collaboration come to life in routine diagnostics. Fimlab is a true pioneer in Finland in adopting AI to enhance pathology diagnostics. It is an honor to contribute to this progressive step in our home country,” says Jukka Tapaninen, CEO of Aiforia.
Fimlab’s press release published on October 3, 2025, regarding the implementation of AI-assisted diagnostics in pathology: https://fimlab.fi/en/ajankohtaista/fimlab-introduces-ai-assisted-diagnostics-in-pathology/
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com